Mirum Pharmaceuticals Inc

Organisation

950 Tower Lane, Foster City, CA, United States, 94404

Headquarters

Employees

Health Technology

Industry

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.

Price

Target

Mirum Pharmaceuticals Inc (MIRM) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Mirum Pharmaceuticals Inc (MIRM) share price will touch around $124.64 in next 12-months.

Currently 17 wall-street analysts regularly analyze the financials of Mirum Pharmaceuticals Inc on a frequent basis to provide recommendations along with target share price. 17 analysts offering 12-month price forecasts for Mirum Pharmaceuticals Inc (MIRM) have a share price target of $124.64. This median of share price forecast represents a 36.92% upside from the latest price of $91.03 as on 19.03.26.

Mirum Pharmaceuticals Inc (MIRM) Share Price Forecast

Home

US Stocks

Mirum Pharmaceuticals Inc (MIRM)

Mirum Pharmaceuticals Inc Stock Forecast

Mirum Pharmaceuticals Inc Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Mirum Pharmaceuticals Inc (MIRM): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Mirum Pharmaceuticals Inc's share price and its median forecast price. As on 19.03.26, the difference is -32.1%

Mirum Pharmaceuticals Inc Forecast and Target Price

Mirum Pharmaceuticals Inc (MIRM) Share Price Forecast

Mirum Pharmaceuticals Inc (MIRM) Price vs Consensus Price Target

Mirum Pharmaceuticals Inc (MIRM) Share Price Forecast v/s Share Price Today

Mirum Pharmaceuticals Inc (MIRM): Difference between Current Price & Median Forecasted Price

Mirum Pharmaceuticals Inc (MIRM) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price